イメージ
大分大学医学部附属病院薬剤部
 
業 績(原著論文)
原著論文(2020年~)
  • 2020年       

    ◎Pharmacokinetic and toxicodynamic evaluation of 5-fluorouracil administration after major hepatectomy in a rat model. Tada K, Iwashita Y, Shiraiwa K, Uchida H, Oshima Y, Sato Y, Nakanuma H, Hirashita T, Masuda T, Endo Y, Takeuchi Y, Ohta M, Itoh H, Inomata M. Cancer Chemotherapy and Pharmacology, 85(2), 345-352 (2020)

    ◎Venous thromboembolisms and rheology in ovarian cancer patients after postoperative adjuvant paclitaxel and carboplatin therapy. Suzuki K, Sato Y, Nakahara R, Tatsuta R, Tanaka R, Itoh H. Pharmazie, 75(5), 205-207 (2020)

    ◎Sensitive and selective quantification of mid-regional proadrenomedullin in human plasma using ultra-performance liquid chromatography coupled with tandem mass spectrometry. Iwao M, Suzuki Y, Tanaka R, Koyama T, Ozaki E, Nakata T, Aoki K, Fukuda A, Sato Y, Kuriyama N, Fukunaga N, Sato F, Katagiri F, Ohno K, Shibata H, Mimata H, Itoh H. J Pharm Biomed Anal. 183, 113168 (2020)

    ◎Simultaneous quantification of coproporphyrin-I and 3-carboxy-4-methyl-5-propyl-2-furanpropanoic acid in human plasma using ultra-high performance liquid chromatography coupled to tandem mass spectrometry. Suzuki Y, Sasamoto Y, Yoshijima C, Tanaka R, Ono H, Ando T, Shin T, Mimata H, Itoh H, Ohno K. J Pharm Biomed Anal. 184, 113202 (2020)      

    ◎Changes in redox state of albumin before and after kidney transplantation in patients with end-stage renal disease. Tanaka R, Imafuku T, Suzuki Y, Nishida K, Matsusaka K, Shin T, Sato Y, Ishima Y, Watanabe H, Mimata H, Maruyama T, Itoh H. Clin Biochem, 81, 20-26 (2020)

    ◎テジゾリドによる血小板減少症が疑われた大腿骨頸部骨折後周囲膿瘍の1例  安東大智, 山村亮太, 埜口貴弘, 宗 広樹, 泊 一秀 日病薬誌, 56(6), 674-678(2020)

    ◎肝細胞がん患者を対象とした薬剤師によるlenvatinib外来への介入とその有用性の検討 小野寛之,龍田涼佑,中原良介,田中遼大,伊東弘樹 医療薬学,46(6), 303-313 (2020)

    ◎In vivo evaluation of drug dialyzability in a rat model of hemodialysis. Fukunaga M, Kadowaki D, Mori M, Hagiwara S, Narita Y, Saruwatari J, Tanaka R, Watanabe H, Yamasaki K, Taguchi K, Ito H, Maruyama T, Otagiri M, Hirata S. PLoS One, 15(6), e0233925 (2020)

    ◎Effects of dose and type of corticosteroids on the divergence between estimated glomerular filtration rates derived from cystatin c and creatinine. Tsushita H, Tanaka R, Suzuki Y, Sato Y, Itoh H. J Clin Pharm Ther, 45(6), 1390-1397 (2020)

    ◎A prospective study on the usefulness of initial voriconazole dose adjustment based on CYP2C19 gene polymorphism analysis. Tanaka R, Fujioka T, Suzuki Y, Iwao M, Itoh H. Chemotherapy, 65(3-4):59-64 (2020)

    ◎精神疾患患者に対するオセルタミビルリン酸塩予防投与の安全性についての検討 亀井進太郎,田中遼大,岩田裕明,龍田涼佑,伊東弘樹 日病薬誌, 56(9), 1012-1019 (2020)

    ◎硫酸マグネシウムの低用量併用によりベクロニウムの用量低減が示唆された破傷風の1例 山村亮太, 安東大智, 五十川達哉, 黒瀬孝二, 中尾龍之介, 添田徹, 伊東弘樹, 迫祐介 日臨救急医会誌, 23, 806-11(2020)

    ◎九州・山口地区の医療機関におけるClostridioides (Clostridium)difficile感染症の診療に関する実態調査 今村政信、藤井裕史、福重友理、山崎博史、入江利行、野中敏治、伊東弘樹、室高広、喜多岡洋樹、茂見茜里、北原隆志 九州薬学会雑誌 74,49-52(2020)

    ◎Population pharmacokinetic analysis of doripenem for Japanese patients in intensive care unit. Nonoshita K, Suzuki Y, Tanaka R, Kaneko T, Ohchi Y, Sato Y, Yasuda N, Goto K, Kitano T, Itoh H. Sci Rep, 10(1), 22148 (2020)

  • 2021年

    ◎双極性障害の不眠症状に対し、ベンゾジアゼピン系睡眠薬で改善が認められず、抑肝散が有効であった1症例 川中理香子, 亀井進太郎, 田中遼大, 釘宮毅, 河野健太郎, 龍田涼佑, 寺尾岳, 伊東弘樹 日病薬誌, 57(1), 24-30 (2021)

    ◎多剤投与中にレベチラセタムによる汎血球減少症が疑われた高齢発症てんかんの1例 五十川達哉,山村亮太,藤井一憲,安東大智,中尾龍之介,中村祐太 日病薬誌, 57(2),192-197 (2021)

    ◎High-throughput and wide-range simultaneous determination of linezolid, daptomycin and tedizolid in human plasma using ultra-performance liquid chromatography coupled to tandem mass spectrometry. Tanaka R, Kai M, Goto K, Ohchi Y, Yasuda N, Tatsuta R, Kitano T, Itoh H. J Pharm Biomed Anal, 194, 113764 (2021)

    ◎Mid-regional pro-adrenomedullin is a novel biomarker for arterial stiffness as the criterion for vascular failure in a cross-sectional study. Koyama T, Kuriyama N, Suzuki Y, Saito S, Tanaka R, Iwao M, Tanaka M, Itoh H, Ihara M, Shindo T, Uehara R. Sci Rep, 11(1), 305 (2021)

    ◎Simultaneous quantification method for 5-FU, uracil, and tegafur using UPLC-MS/MS and clinical application in monitoring UFT/LV combination therapy after hepatectomy. Shiraiwa K, Suzuki Y, Uchida H, Iwashita Y, Tanaka R, Iwao M, Tada K, Hirashita T, Masuda T, Endo Y, Inomata M, Itoh H. Sci Rep, 11(1), 3132 (2021)

    ◎A retrospective test for a possible relationship between linezolid-induced thrombocytopenia and hyponatremia. Tanaka R, Suzuki Y, Morinaga Y, Iwao M, Takumi Y, Hashinaga K, Tatsuta R, Hiramatsu K, Kadota J, Itoh H. J Clin Pharm Ther, 46(2), 343-351 (2021)

    ◎Significant elevation of free itraconazole concentration at onset of adverse effects: a case report. Tanaka R, Suzuki Y, Matsumoto H, Yamasue M, Umeki K, Hashinaga K, Tatsuta R, Hiramatsu K, Kamei K, Kadota J, Itoh H. Clin Case Rep, 9(3), 1187-1192 (2021)

    ◎Effect of S-1 on blood levels of phenobarbital and phenytoin: A case report. Shiraiwa K, Ono H, Tanaka R, Fujinaga A, Hiratsuka T, Tatsuta R, Inomata M, Itoh H. Clin Case Rep, 9(3):1514-1517 (2021)

    ◎プロポフォールの院内使用手順の策定と評価 山村亮太, 龍田涼佑, 中原良介, 衛藤大輝, 森永裕子, 田中遼大, 北野敬明, 平松和史, 伊東弘樹 日病薬誌, 57(4),401-406 (2021)

    ◎Development of a High-Throughput Quantification Method for Pazopanib Using Ultra-Performance Liquid Chromatography-Tandem Mass Spectrometry and Its Clinical Application in Patients with Soft Tissue Tumors. Shiraiwa K, Suzuki Y, Tanaka K, Kawano M, Iwasaki T, Matsumoto A, Tanaka R, Tatsuta R, Tsumura H, Itoh H. Ther Drug Monit. 43:416-421 (2021)

    ◎A broad range high-throughput assay for lenvatinib using ultra-high performance liquid chromatography coupled to tandem mass spectrometry with clinical application in patients with hepatocellular carcinoma. Sueshige Y, Shiraiwa K, Honda K, Tanaka R, Saito T, Tokoro M, Iwao M, Endo M, Arakawa M, Tatsuta R, Murakami K, Itoh H. Ther Drug Monit. 43(5):664-671 (2021)

    ◎Simultaneous quantification of plasma levels of 12 antimicrobial agents including carbapenem, anti-methicillin-resistant Staphylococcus aureus agent, quinolone and azole used in intensive care unit using UHPLC-MS/MS method. Kai M, Tanaka R, Suzuki Y, Goto K, Ohchi Y, Yasuda N, Tatsuta R, Kitano T, Itoh H. Clin Biochem, 90, 40–49 (2021)

    ◎テリパラチドバイオシミラーの治療学的安全性および薬剤費削減効果の検討 龍田涼佑、衛藤大輝、田中遼大、伊東弘樹 診療と新薬, 58, 8-14 (2021)

    ◎カテーテル先端位置の変更と経腸栄養剤の影響軽減によりバルプロ酸ナトリウムの血中濃度が上昇した抗NMDA受容体脳炎後遺症の1例 山村亮太、森永裕子、柴田智隆、伊東弘樹 JSPEN誌,3(3),188-193(2021)

    ◎Pharmacokinetic and adsorptive analyses of administration of oral voriconazole suspension via enteral feeding tube in intensive care unit patients. Tanaka R, Eto D, Goto K, Ohchi Y, Yasuda N, Suzuki Y, Tatsuta R, Kitano T, Itoh H. Biol Pharm Bull, 44(5), 737-741 (2021)

    ◎Sensitive, wide-range and high-throughput quantification of cyclosporine in whole blood using ultra-performance liquid chromatography coupled to tandem mass spectrometry and comparison with an antibody-conjugated magnetic immunoassay. Watanabe T, Tanaka R, Ono H, Suzuki Y, Tatsuta R, Itoh H. Biomed Chromatogr, 35(8), e5128 (2021)

    ◎リネゾリドからテジゾリドへの切り替え後に血小板数が回復した2症例 上野希望, 田中遼大, 山村亮太, 龍田涼佑, 伊東弘樹 日病薬誌, 57(7),742-748 (2021)

    ◎トラスツズマブの先行バイオ医薬品とバイオ後続品の治療学的安全性の比較 龍田涼佑,炭本隆宏,中原良介,田中遼大,伊東弘樹 癌と化学療法 48巻7号, 945-949 (2021)

    ◎Association of CYP3A5 polymorphisms and parathyroid hormone with blood level of tacrolimus in patients with end-stage renal disease. Tanaka R, Suzuki Y, Watanabe H, Fujioka T, Hirata K, Shin T, Ando T, Ono H, Tatsuta R, Mimata H, Maruyama T, Itoh H. Clin Transl Sci, 14(5), 2034-2042 (2021)

    ◎Successful determination of imatinib re-administration dosage by therapeutic drug monitoring in a case of chronic myeloid leukemia initiating dialysis for acute renal dysfunction. Nakahara R, Sumimoto T, Tanaka R, Ogata M, Itoh H. Clinical Case Reports. Clin Case Rep, 9(8):4357-4361 (2021)

    ◎病棟定数配置薬の変更による睡眠導入剤の適正使用推進と転倒転落件数への影響に関する調査 中原良介, 山村亮太, 龍田涼佑, 田中遼大, 平松和史,伊東弘樹 日病薬誌, 57(9),974-980 (2021)

    ◎Factors influencing plasma coproporphyrin-I concentration as biomarker of OATP1B activity in patients with rheumatoid arthritis. Ono H, Tanaka R, Suzuki Y, Oda A, Ozaki T, Tatsuta R, Maeshima K, Ishii K, Ohno K, Shibata H, Itoh H. Clin Pharmacol Ther, 110(4), 1096-1105 (2021)

    ◎Sensitive quantification of free pazopanib using ultra-high performance liquid chromatography coupled to tandem mass spectrometry and assessment of clinical application. Matsumoto A, Shiraiwa K, Suzuki Y, Tanaka K, Kawano M, Iwasaki T, Tanaka R, Tatsuta R, Tsumura H, Itoh H. J Pharm Biomed Anal. 206, 114348 (2021)

    ◎Maximum plasma concentration of lenvatinib is useful for predicting thrombocytopenia in patients treated for hepatocellular carcinoma. Endo M, Honda K, Saito T, Shiraiwa K, Sueshige Y, Tokumaru T, Iwao M, Tokoro M, Arakawa M, Tanaka R, Tatsuta R, Seike M, Itoh H, Murakami K. World J Oncol. 12(5), 165-172 (2021)

    ◎薬剤投与が発症に関与したと思われる気腫性胃炎の1例 松成 修,鍋田祐介,山村亮太,柴田智隆 JSPEN誌,3(4),254-259(2021)

    ◎Association between MR-proADM concentration and treatment intensity of antihypertensive agents in chronic kidney disease patients with insufficient blood pressure control. Iwao M, Tanaka R, Suzuki Y, Nakata T, Aoki K, Fukuda A, Fukunaga N, Tatsuta R, Ohno K, Shibata H, Itoh H. Sci Rep. 11(1), 21931 (2021)

    ◎A case of improvement of clozapine-induced low leukocyte counts by adenine, cepharanthin and ninjin-yoei-to in a patient with treatment-resistant schizophrenia. Kamei S, Tanaka R, Hirakawa H, Iwao M, Kawanaka R, Tatsuta R, Terao T, Itoh H. J Pharm Health Care Sci. 7(1), 45 (2021)

  • 2022年

    ◎High-throughput simultaneous quantification of five azole anti-fungal agents and one active metabolite in human plasma using ultra-high-performance liquid chromatography coupled to tandem mass spectrometry. Tanaka,R, Shiraiwa K, Takano K, Ogata M, Honda S, Yoshida N, Okuhiro K, Yoshida M, Narahara K, Kai M, Tatsuta R, Itoh H. Clin Biochem. 99, 87-96 (2022)

    ◎Response to "iPTH is not a significant factor influencing the Tacrolimus C/D ratio". Tanaka R, Suzuki Y, Watanabe H, Fujioka T, Hirata K, Shin T, Ando T, Ono H, Tatsuta R, Mimata H, Maruyama T, Itoh H. Clin Transl Sci. 15(4), 807-808 (2022)

    ◎Development of a Sensitive and High-throughput Assay for Simultaneous Quantification of Five Tyrosine Kinase Inhibitors and Two Active Metabolites in Human Plasma Using Ultra-performance Liquid Chromatography Coupled to Tandem Mass Spectrometry. Sumimoto T, Nakahara R, Suzuki Y, Tanaka R, Yoshida N, Ogata M, Itoh H. Ther Drug Monit. 44(3):419-429 (2022)

    ◎スルファメトキサゾール・トリメトプリムのニューモシスチス肺炎発症抑制量と治療量の違いによりワルファリン使用時のPT-INRへの影響に違いが認められた一症例 森永裕子,田中遼大,龍田涼佑,伊東弘樹 医薬品安全性学, 7(2),115-123 (2022)

    ◎未承認新規医薬品等の臨床使用における管理体制の構築とその後の中長期的な安全性の評価 龍田涼佑,中原良介,田中遼大,平松和史,伊東弘樹 日病薬誌, 58(3),305-312 (2022)

    ◎マニュアルの制定を契機としたカリウム補給注射剤における適正使用の推進 山村亮太,中原良介,龍田涼佑,上野希望,田中遼大,北野敬明,松成修, 平松和史,伊東弘樹 日病薬誌, 58(4), 416-420(2022)

    ◎Exacerbation of cancer pain after administering immune checkpoint inhibitor in a patient taking opioids: A case report. Sumimoto T, Tanaka R, Shiraiwa K, Tatsuta R, Itoh H. J Clin Pharm Ther. 47, 552-555 (2022)

    ◎Association of vancomycin trough concentration and clearance with febrile neutropenia in pediatric patients. Amano E, Tanaka R, Ono H, Tatsuta R, Hashimoto T, Hiramatsu K, Itoh H. Ther Drug Monit. 44, 543-551 (2022)

    ◎High-Sensitivity and High-Throughput Quantification of Everolimus in Human Whole Blood using Ultra-High-Performance Liquid Chromatography Coupled with Tandem Mass Spectrometry. Miyagi C, Tanaka R, Hirata K, Watanabe T, Tatsuta R, Miyamura S, Itoh H. Ther Drug Monit. 44(5), 633-640 (2022)

    ◎Highly sensitive simultaneous quantification of indoxyl sulfate and 3-carboxy-4-methyl-5-propyl-2-furanpropanoic acid in human plasma using ultra-high performance liquid chromatography coupled with tandem mass spectrometry. Oda A, Suzuki Y, Sato B, Sato H, Tanaka R, Ono H, Ando T, Shin T, Mimata H, Itoh H, Ohno K. J Sep Sci. 45(10), 1672-1682 (2022)

    ◎Sensitive UHPLC-MS/MS quantification method for 4β- and 4α-hydroxycholesterol in human plasma for accurate CYP3A phenotyping. Suzuki Y, Oda A, Negami J, Toyama D, Tanaka R, Ono H, Ando T, Shin T, Mimata H, Itoh H, Ohno K. J Lipid Res. 63(3), 100184 (2022)

    ◎Cathepsin G-induced malignant progression of MCF-7 cells involves suppression of PAF signaling through induced expression of PAFH1B2. Tanigawa K, Kiriya M, Hayashi Y, Shinden Y, Kijima Y, Natsugoe S, Sumimoto T, Morimoto-Kamata R, Yui S, Hama K, Yokoyama K, Nakamura Y, Suzuki K, Nojiri H, Inoue K, Karasawa K. Biochim Biophys Acta Mol Cell Biol Lipids. Aug;1867(8):159164, (2022)

    ◎Sustained suppression of enterohepatic circulation of mycophenolic acid by antimicrobial-associated diarrhea in a kidney transplant recipient with Crohn's disease: A case report. Tanaka R, Matsumoto A, Tatsuta R, Ando T, Shin T, Mimata H, Itoh H. Clin Case Rep. 10(6), e05914 (2022)

    ◎Impact of inflammation on intra-individual variation in trough voriconazole concentration in patients with hematological malignancies. Maeda Y, Tanaka R, Tatsuta R, Takano K, Hashimoto T, Ogata M, Hiramatsu K, Itoh H. Biol Pharm Bull. 45(8), 1084-1090 (2022)

    ◎A validated UHPLC-MS/MS method for quantification of total and free tedizolid concentrations in human plasma. Tanaka R, Kai M, Shinohara S, Tatsuta R, Itoh H. J Pharm Biomed Anal, 219, 114929 (2022)

    ◎間接ビリルビン値の推移に着目することで早期発見につながったPIPC/TAZによる溶血性貧血の1例 山村亮太, 梅津成貴, 塚本菜穂, 上野希望, 田中遼大, 龍田涼佑, 石井圭亮, 坂本照夫, 伊東弘樹 日病薬誌, 58(12), 1405-1409(2022)

    ◎血清Mg濃度のトラフおよびピーク値の測定が有用であったセツキシマブによる低Mg血症の1例 衛藤大輝, 山村亮太, 中原良介, 白岩健, 龍田涼佑, 田中遼大, 平野隆, 伊東弘樹 日病薬誌, 58(12), 1445-1449(2022)

  • 2023年

    ◎UHPLC-MS/MS method for simultaneous quantification of doripenem, meropenem, ciprofloxacin, levofloxacin, pazufloxacin, linezolid and tedizolid in filtrate during continuous renal replacement therapy. Kai M, Tanaka R, Suzuki Y, Goto K, Ohchi Y, Yasuda N, Tatsuta R, Kitano T, Itoh H. J Clin Lab Anal, 37(1), e24815. (2023)

    ◎Positive correlation between organic anion transporter 1B function indicated by plasma concentration of coproporphyrin-I and blood concentration of cyclosporin A in real-world patients. Watanabe T, Tanaka R, Suzuki Y, Sato H, Negami J, Yoshijima C, Oda A, Ono H, Tatsuta R, Ohno K, Itoh H. Br J Clin Pharmacol. 89(5), 1672-1681 (2023)

    ◎Evaluation of effects of indoxyl sulfate and parathyroid hormone on CYP3A activity considering the influence of CYP3A5 gene polymorphisms. Oda A, Suzuki Y, Yoshijima C, Sato H, Tanaka R, Ono H, Tatsuta R, Ando T, Shin T, Itoh H, Ohno K. Br J Clin Pharmacol, 89(12), 3648-3658 (2023)

    ◎Comparison of incidence of hyponatremia between linezolid and vancomycin by propensity score matching analysis. Tanaka R, Morinaga Y, Iwao M, Tatsuta R, Hashimoto T, Hiramatsu K, Itoh H. Biol Pharm Bull, 46(10), 1365-1370 (2023)

    ◎潜在的なVK欠乏状態へSBT/CPZを使用したことによる血液凝固障害の1例 山村亮太,上野希望,松本祐欣,塚本菜穂,田中遼大,龍田涼佑,石井圭亮,坂本照夫,伊東弘樹 九州薬学会雑誌,77,53-57(2023)

    ◎オビヌツズマブ+ベンダムスチン療法施行後に腫瘍崩壊症候群による急性腎・肝障害を呈した濾胞性リンパ腫の一症例 白岩健, 田中遼大, 龍田涼佑, 伊東弘樹 九州薬学会雑誌, 77, 59-62 (2023)

    ◎ペメトレキセドの先発品と後発品の調製効率ならびに治療学的安全性の比較 龍田涼佑,炭本隆宏,白岩健,中原良介,田中遼大,伊東弘樹 癌と化学療法誌 in press.(2023)

  • 2024年

    ◎Rapid and simple quantification of belimumab in human plasma using ultra-high performance liquid chromatography with tandem mass spectrometry. Yoshijima C, Suzuki Y, Tanaka R, Ono H, Oda A, Ozaki T, Shibata H, Itoh H, Ohno K. Clin Biochem, 124, 110706 (2024)

    ◎Relationship of plasma 3-carboxy-4-methyl-5-propyl-2-furanpropanoic acid concentration with OATP1B activity in patients with chronic kidney disease. Ono H, Tanaka R, Suzuki Y, Oda A, Sato H, Tatsuta R, Ando T, Shin T, Ohno K, Itoh H. Clin Transl Sci, in press (2024)

    ◎Usefulness of belimumab in adult patients with systemic lupus erythematosus evaluated using single indexes: a meta-analysis and systematic review. Yoshijima C, Suzuki Y, Oda A, Tanaka R, Ono H, Itoh H, Ohno K. Curr Ther Res Clin Exp, in press (2024)

    ◎Evaluation of the usefulness of plasma 4β-hydroxycholesterol concentration normalized by 4α-hydroxycholesterol for accurate CYP3A phenotyping. Oda A, Suzuki Y, Sato H, Koyama T, Nakatochi M, Momozawa Y, Tanaka R, Ono H, Tatsuta R, Ando T, Shin T, Wakai K, Matsuo K, Itoh H, Ohno K. Clin Transl Sci, in press (2024)